Wellington Partners announces first closing of new life science fund

Thursday, September 20, 2012 07:31 AM

Wellington Partners, a pan-European venture capital firm, announced the successful first closing of its new Wellington Partners IV Life Science Fund, which has attracted commitments from investors of $91 million.

With a target size of $156 million, this new fund is expected to be significantly larger than the previous Wellington Partners III Life Science Fund, which raised $102 million. The Wellington Partners life science team—comprised of general partners Rainer Strohmenger, Erich Schlick, Regina Hodits, Harald Keller, Ernst Mannheimer and Rolf Dienst—will focus on investing these funds in innovative companies in the areas of medical devices, diagnostics and biotechnology on a pan-European basis.

The new fund has attracted investors from Germany, Switzerland, Austria, Benelux, France, the U.K., the U.S. and the Middle East. Among the main investors in Wellington Partners IV Life Science are the European Investment Fund (EIF), LfA Foerderbank Bayern, Austria Wirtschaftsservice GmbH and several large family offices. Despite the challenging financial environment, investors have been convinced by the opportunity to benefit from participation in companies developing highly innovative products in a major growth market as well as by the excellent track record of the Wellington Partners life science investment team.

"This first closing of our new, larger fund in a challenging financial environment is a big success and reflects the strength of our team and our approach to investment in this complex market,” Strohmenger. “Numerous renowned investors are trusting in our ability to create value by selectively investing in the most promising and innovative private life science companies in Europe. The market environment is highly favorable because a majority of investors are currently neglecting this segment despite the fact that the life science market will be one of the most important growth drivers in the coming years. This has led to a scarcity of capital, moderate entry valuations and hence the opportunity to generate outstanding returns for those investors who are willing to act anti-cyclically. This strategy has been pursued by Wellington Partners highly successfully for many years."

Wellington Partners was an early investor in Swiss-based listed pharma player Actelion and in mtm Laboratories, a German diagnostics company focusing on cervical cancer screening, which was acquired by Roche in 2011 for up to $248 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs